Venetoclax Patient Medication Instructions

Drug name: Venetoclax (Venetoclax)

1.Indications:

Venetoclax is mainly used to treat the following diseases:

Chronic lymphocytic leukemia (CLL): Includes patients who have become resistant to or relapsed from other treatment options, particularly those with 17p chromosomal deletions or TP53 mutations.

Small lymphocytic lymphoma (SLL): used to treat relapsed or refractory cases.

Acute myeloid leukemia (AML): It is especially suitable for elderly patients who cannot tolerate traditional chemotherapy or patients with other comorbidities.

2.Drug mechanism

Venetoclax is a selective BCL-2 inhibitor that promotes cancer cell apoptosis by targeting and inhibiting the Bcell lymphoma-2 (BCL-2) protein. BCL-2 is an anti-apoptotic protein highly expressed in cancer cells, preventing natural cell death. By inhibiting this protein, venetoclax can effectively reduce the survival of malignant cells and enhance the apoptosis of cancer cells.

3.Usage and Dosage

Initial dose: The dose of venetoclax is usually started at a low dose and titrated up to reduce the risk of tumor lysis syndrome (TLS).

Recommended dosage:

CLL/SLLPatients: The usual starting dose is 20 mg once daily, with gradual increases to a target dose of 400 mg once daily.

Patients with AML: Starting dose is 100 mg once daily, gradually increasing to 400 mg once daily, usually in combination with azacitidine or decitabine.

Dosage method: Venetoclax is an oral preparation and it is recommended to take it with food to enhance the absorption of the drug.

4.Adverse reactions

The use of venetoclax may cause the following adverse reactions:

Common side effects: neutropenia (may lead to increased risk of infection), anemia, nausea, vomiting, fatigue, diarrhea or constipation

Serious side effects:

Tumor lysis syndrome (TLS): may lead to electrolyte imbalance, renal failure, etc. Electrolyte levels need to be monitored and appropriate measures taken.

Infections: Due to immunosuppression, patients are at increased risk for infections, including bacterial, viral, and fungal infections.

5.Precautions for use

Monitoring: After the start of treatment, blood routine, liver and kidney function and electrolyte levels need to be monitored regularly, especially in the early stages of treatment. Monitoring of neutrophil, platelet, and electrolyte levels is critical to prevent potentially serious side effects.

Dose adjustment: If serious adverse reactions occur, the dose needs to be adjusted or treatment suspended. Based on the patient's tolerance and hematological parameters, the doctor will decide whether to continue treatment.

Risk of Tumor Lysis Syndrome: Early in treatment, especially before starting high-dose therapy, make sure the patient is well hydrated and take precautions during monitoring.

6.Interaction

Venetoclax may interact with other drugs, especially those that affectCYP3A4enzyme. While using venetoclax, patients should inform their doctor about all medications they are taking, including prescription drugs, over-the-counter drugs, and herbal supplements. Strong CYP3A4inhibitors (such as certain antibiotics, antifungals, and antiviral drugs) may increase the concentration of venetoclax, so coadministration should be avoided or the dosage should be adjusted.

7.Taboo

Contraindicated in patients allergic to venetoclax or its components.

Pregnant and lactating women should use with caution and alternative treatment options should be considered if necessary.

8.Pregnant and lactating period

Pregnant women: The safety of venetoclax has not been determined. Pregnant women should use it under the guidance of a doctor to evaluate the risks and benefits.

Lactation: It is unknown whether venetoclax is excreted in breast milk and it is recommended to avoid use during breastfeeding.

Venetoclax is an effective targeted therapy that offers new hope in treating certain types of blood cancers. However, patients should strictly follow the medication regimen under the guidance of a doctor during use and conduct regular monitoring to ensure safety and therapeutic effect. During the use of venetoclax, any discomfort or abnormality should be communicated to the doctor in time to ensure appropriate treatment and support.